Nasal allergies and beyond: a clinical review of the pharmacology, efficacy, and safety of mometasone furoate


Dr. C. van Drunen, PhD, Head of ENT research, room L3-104-2, Department of Otorhinolaryngology, Academic Medical Center, PO-box 22660, NL-1100 DD Amsterdam, The Netherlands.


Mometasone furoate nasal spray (MFNS; Nasonex®, Schering-Plough Corporation, Kenilworth, NJ, USA) is an effective and well-tolerated intranasal corticosteroid approved for the prophylactic treatment of seasonal allergic rhinitis, and the treatment of perennial allergic rhinitis. MFNS is a potent molecule with a rapid onset of action and excellent safety and efficacy profiles. Having recently received approval for the treatment of nasal polyposis, data indicate that MFNS may also be effective in rhinosinusitis.